Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy

Urology

Volumn 70, Issue 1, 2007, Pages 122-126

  Ryan, Christopher W ^a   Huo, Dezheng ^b   Stallings, James W ^c   Davis, Ronald L ^d   Beer, Tomasz M ^a   McWhorter, Laura T ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Arkansas Urology   (United States)

^d The Urology Center   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CAFFEINE; CALCIUM; CORTICOSTEROID; GONADORELIN AGONIST; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; BONE DENSITY; BONE METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMUR NECK; FRACTURE; HORMONAL THERAPY; HUMAN; LIFESTYLE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE LINEAR REGRESSION ANALYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SMOKING; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; HUMANS; IMIDAZOLES; LIFE STYLE; MALE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 34447559432     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.026     Document Type: Article

References (22)

1. Mittan D., Lee S., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 (2002) 3656-3661
2. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
3. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 (2002) 2361-2367
4. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607-611
5. Maillefert J.F., Sibilia J., Michel F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161 (1999) 1219-1222
6. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
7. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181-186
8. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439-444
9. Smith M.R., McGovern F.J., Fallon M.A., et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91 (2001) 2238-2245
10. Conde F.A., Sarna L., Oka R.K., et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 64 (2004) 335-340
11. Orwoll E.S. Treatment of osteoporosis in men. Calcif Tissue Int 75 (2004) 114-119
12. Agarwal M.M., Khandelwal N., Mandal A.K., et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103 (2005) 2042-2052
13. Ryan C.W., Huo D., Demers L.M., et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176 (2006) 972-978
14. Kanis J.A., Melton III L.J., Christiansen C., et al. The diagnosis of osteoporosis. J Bone Miner Res 9 (1994) 1137-1141
15. Dawson-Hughes B., Harris S.S., Krall E.A., et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337 (1997) 670-676
16. Orwoll E.S., Oviatt S.K., McClung M.R., et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 112 (1990) 29-34
17. National Osteoporosis Foundation. Men. Available at: http://www.nof.org/men/vol. Accessed October 12, 2006.
18. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
19. Spencer H., Rubio N., Rubio E., et al. Chronic alcoholism: frequently overlooked cause of osteoporosis in men. Am J Med 80 (1986) 393-397
20. Feskanich D., Korrick S.A., Greenspan S.L., et al. Moderate alcohol consumption and bone density among postmenopausal women. J Womens Health 8 (1999) 65-73
21. Holbrook T.L., and Barrett-Connor E. A prospective study of alcohol consumption and bone mineral density. BMJ 306 (1993) 1506-1509
22. Siris E.S., Miller P.D., Barrett-Connor E., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286 (2001) 2815-2822